A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 †
Titel:
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 †
Auteur:
Chu, Q. S.-C. Nielsen, T.O. Alcindor, T. Gupta, A. Endo, M. Goytain, A. Xu, H. Verma, S. Tozer, R. Knowling, M. Bramwell, V.B. Powers, J. Seymour, L.K. Eisenhauer, E.A.